In this episode, listeners receive a ticket to ride the Copenhagen Metro to the 2016 Congress of ESMO, the European Society for Medical Oncology.

Along the way we hear from experts about targeting ovarian cancer and some of the latest data on PARP inhibitors, biomarkers and novel immunotherapy combinations.

Included are excerpts from interviews with Dr Rebecca Kristeleit (UCL), Dr Johnathan Lancaster (Myriad Genetic Laboratories), Dr Priti Hegde (Genentech) and Professor George Coukos (Lausanne).

All of the interviews were previously published on Biotech Strategy Blog (subscription required).

You can find additional information in the show notes on http://noveltargets.com

Copyright © Blue Ice Publishing LLC, 2016. All Rights Reserved.